AUSTIN, Texas, Oct. 8, 2025 /PRNewswire/ — Hahn Labs, a leader in data-driven marketing and AI innovation, today announces the launch of its new AI-powered healthcare call automation solution designed to transform the open enrollment experience for health plans, members, and providers.
Every year, open enrollment brings overwhelming spikes in call volume. Members wait on hold for up to 20 minutes just to get answers to common questions. Agents spend countless hours repeating information, and call centers struggle to scale quickly enough to keep pace. The result: frustrated members, stressed employees, and rising costs.
Hahn Labs’ AI solution changes that equation. Using HIPAA-compliant, multilingual voice and text agents, the system can instantly resolve up to 80% of inbound calls—cutting wait times from 20 minutes to less than two. Urgent issues are escalated immediately to live agents, while non-urgent inquiries can be scheduled for convenient call-backs. The platform integrates seamlessly with IVR, CRM, and HMS systems, delivering consistent answers with full audit trails and reporting.
The impact is measurable:
‘Our healthcare AI agents don’t just reduce call volume, they elevate the member experience,” said Tim Weinheimer, Chief Marketing Officer at Hahn. ‘We help health plans turn open enrollment from a pain point into a trust-building opportunity.’
About Hahn and Hahn Labs
Hahn is an Austin-based marketing and communications agency specializing in data-powered strategies that help essential brands earn trust and achieve measurable impact. Hahn is the winner of the 2024 Digital Agency of the Year North American SABRE Award. Hahn Labs is the innovation and measurement arm of Hahn, dedicated to developing predictive tools and ROI-driven models that help brands quantify the impact of communications and make data-informed marketing decisions. Hahn partners with purpose-driven organizations nationwide to deliver clarity, creativity, and results.
SOURCE HAHN, TEXAS COMMUNICATIONS
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…